

# Supporting Information

## **Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides**

Kariem Ezzat <sup>1\*</sup>, Yoshitsugu Aoki <sup>1,11\*</sup>, Taeyoung Koo <sup>1,2,3</sup>, Graham McClorey <sup>1</sup>, Leif Benner <sup>1</sup>, Anna Coenen-Stass <sup>1</sup>, Liz O'Donovan <sup>4</sup>, Taavi Lehto <sup>5</sup>, Antonio Garcia-Guerra<sup>6</sup>, Joel Nordin<sup>5</sup>, Amer F. Saleh <sup>4</sup>, Mark Behlke<sup>7</sup>, John Morris <sup>1</sup>, Aurelie Goyenvalle<sup>8</sup>, Branislav Dugovic<sup>9</sup>, Christian Leumann<sup>9</sup>, Siamon Gordon<sup>10</sup>, Michael J. Gait<sup>4</sup>, Samir El-Andaloussi<sup>1,5</sup> and Matthew JA Wood <sup>1</sup>.

<sup>1</sup>Department of Physiology, Anatomy and Genetics, University of Oxford, OX13QX, Oxford, UK

<sup>2</sup>Center for Genome Engineering, Institute for Basic Science, Seoul, South Korea

<sup>3</sup>Functional Genomics, University of Science and Technology, Daejeon, South Korea

<sup>4</sup>Medical Research Council Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK

<sup>5</sup>Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden

<sup>6</sup>Department of Physics, University of Oxford

<sup>7</sup>Integrated DNA Technologies (IDT), Coralville, Iowa, USA

<sup>8</sup>Université de Versailles Saint Quentin, Montigny le Bretonneux, France

<sup>9</sup>Department of Chemistry & Biochemistry, University of Bern, Bern, Switzerland


<sup>10</sup>Sir William Dunn School of Pathology, University of Oxford, OX1 3RE, Oxford, UK

<sup>11</sup>National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan

\*These authors contributed equally to this work.


Correspondence should be addressed to: [matthew.wood@dpag.ox.ac.uk](mailto:matthew.wood@dpag.ox.ac.uk)

# Figure S1.




**Figure S1.** (A) DLS analysis of tcDNA, 2'OMe and PPMO in the presence of physiological concentrations of albumin (BSA). Each was measured 3 times (different colors) at final concentration of 500  $\mu\text{M}$  for tcDNA and 2'OMe and 50  $\mu\text{M}$  for PPMO after incubation with albumin solution in PBS at 37  $^{\circ}\text{C}$  for 1h (B) Nanoparticles formed by FITC-labelled tcDNA and PPMO after incubation with full serum for 1h at 37 $^{\circ}$  C and separation via a continuous sucrose gradient visualized by fluorescence microscopy, scale bar = 5  $\mu\text{m}$ . (C) PPMO at the concentration of 50  $\mu\text{M}$  was loaded on a 1.25% agarose gel with ethidium bromide and run in 3 different conditions, TBE, TBE with 4x Tris and TBE with 4x boric acid (BA).

Figure S2.




**Figure S2.** qPCR analysis of SCARAs in (A) C2C12 and (B) H2k *mdx* myoblast or myotube cells. Day 1 levels were set to 100% expression and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control to determine relative RNA expression levels throughout samples, n=3. \*P < 0.05; one-way ANOVA, error bars represent mean  $\pm$  SEM.

Figure S3.



**Figure S3.** (A) Negatively stained TEM pictures of nanoparticles formed by Pip6a-PMO; Bar = 100 nm. (B) Analysis of Pip6a-PMO uptake in the presence of SR ligands. Differentiated C2C12 cells were pretreated with ligands or controls (5  $\mu\text{g}/\text{ml}$  for fucoidin, dextran and chondroitin sulfate, 25  $\mu\text{g}/\text{ml}$  for poly I and poly C) for 1 h and subsequently incubated for 4 h with fluorescein labelled Pip6a-PMO at 250 nm, then the cells were washed and internalization was assessed by fluorescence spectrophotometry. \*\*\*  $P < 0.001$ ; Student's t-test, error bars represent mean  $\pm$  SEM.

# Figure S4.



**Figure S4.** Differentiated C2C12 cells ( $10 \times 10^3/\text{cm}^2$ ) were treated with FITC-labelled ASOs at  $2 \mu\text{M}$  for 24h at (A)  $37^\circ\text{C}$  compared to  $4^\circ\text{C}$ , or (B) in Opti-MEM® compared to differentiation medium with 2% horse serum (2% HS), then the total fluorescence was quantified in each well using spectrophotometry. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; Student's t-test; error bars represent mean  $\pm$  SEM. *Mdx* primary myoblasts seeded in 6 well-plate treated with (C) tcDNA or 2'OMe targeting exon 23 (final concentration  $1.17 \mu\text{M}$ ) or (D) tcDNA or 2'OMe targeting exon 51 (final concentration  $265 \text{ nM}$ ) using lipofectamine 2000 reagent according to manufacturer's protocol. Sequences for the exon 51 skipping ASOs are 5'-UCAAGGAAGAUGGCAUUUCU-3' for 2'OMe, and 5'-TCAAGGAAGATGGCATTCT-3' for tcDNA. The products of nested reverse transcription-PCR (RT-PCR) were examined by electrophoresis on a 2% agarose gel 48 h after transfection.